Cyclo Therapeutics Inc (CYTH) Cotización

CYTH under $2

added sub 1.00 this week at .91 on the gap fill 4Hr chart looks great watching for 1.10 then 1.20 break

$CYTH Swinging this biggest daily and weekly vol in its history today and Phase 3 Positive good results, they've been waiting years for this ..BIG move coming on this Weekly chart break out

Back in at 1.10

PM 1.25 grabs on 3rd phase trials

I'm no expert, again, but this looks like another technical breakout.

Well, I'm no expert, but to me, it looks like a technical breakout is occurring.

I told you all, kaboom! Even more kaboom $20 coming! Big news ahead!

You didnt tell me or anyone here anything. $10 post split is .10 cents presplit which is a price you said we would never see.

I said it would likely go as low as .02 or .03 cents and it did (post split $300 = .03 cents pre-sslpit)

Now you're bragging that the stock might get back to a dime or .20 cents (presplit) price....lol

Anyone who actually follows this thread, and there are a few, know who gave them the gospel.

Kabooom! $20 coming!

Boom! Told you! $10 imminent!

OVER 50% HAIRCUT from pre-split close of $8.60 to $3.60 today ---

Looks like your $2 bucks coming soon ....lol

Look at the 3 year chart -- from ~ $118 to under $4 --->

your prediction for $2 bucks plus now means the stock has to go over $200

I predicted .25 cents -- you mocked
I predicted .10 cents -- you mocked

Looks like we're not headed to .03 cents ($3 post split.


BAAAHHHWAAAAAH!

YOU LOSE!

there you go JellyBelly -- you got your $2.00+
HAPPY NOW???

CTDH moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

Well, finally jellybelly is gonna get his $
2.00+ price...lmao!

CTDH one for 100 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Ha no we were in a few together tho,such as lmki to name 1 kill

Tell me, have we ever vacationed together? if so, what city?

This is the Laz I know lol

Hey JellyBelly (or is it Rick?) -- we came with .014 cents of 2 pennies this morning.

(be patient though, I still think we'll see .02)

Lazarus who?

Buying some 4s

Lol... Uhmmm... You remind me of the analysts who come out and with a SELL recommendation after a stock they're covering has dropped 90%.

On the flip side - same ass-clowns put out a buy reco after a stock has gone up 100%.

Dilution. Sell.

Here's a math question for you JellyBelly (are you smarter than a 2nd grader?)

Stock is .10 cents
Which is closer: .02 cents or $2.00 ???

You have only 30 seconds to figure it out (and no using a calculator or calling a friend)

10Q just released ---

https://www.otcmarkets.com/filing/html?id=14497214&guid=u2EeUegWbjYkc3h

no working capital

negative equity

no news

(looks like time to pass the tin cup again...)

.02 looks more likely to me than a buck at this point.

Good Luck

lololol .... I've been calling a dime and you $2.00 for years. Give it up dood.

Have you noticed the millions of shares dumped by Armistice Capital??

On 9/3/2020 they had 18,808,308 shares

On 9/29.2020 they had 15,795,765

READ the form 4 filings here: https://www.otcmarkets.com/stock/CTDH/disclosure

I wouldn't exactly call that a vote of confidence.

Is it go time? Waiting for $1 when things get cooking!

https://www.businesswire.com/news/home/20201021005674/en/

Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick Disease Type C

October 21, 2020 10:53 AM Eastern Daylight Time
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC) today announced that the company received notification from the US FDA that enrollment can proceed for its Phase 3 global pivotal clinical trial, “A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-ß-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1”.

“We are grateful to the FDA for the positive feedback on our Phase 3 pivotal study design”
Tweet this
“We are very pleased to receive the FDA’s notification that we can proceed with the Phase 3 clinical trial. This announcement signifies the most significant milestone for our company but also for the patients, families and caregivers in the NPC Community as well,” said company CEO N Scott Fine. “We will continue to collaborate with the NPC community as we drive this study forward towards market authorization as rapidly as possible.”

“Through our Fast Track designation, we were able to engage in ongoing collaboration with the US FDA which has enabled us to proceed quickly in the US,” said company Chief Regulatory Officer Michael Lisjak. “We will continue to execute on our parallel efforts with the EMA and other regulatory bodies to achieve a similar outcome on our Phase 3 pivotal program outside the US.”

“We are grateful to the FDA for the positive feedback on our Phase 3 pivotal study design,” said company Chief Scientific Officer and Senior Vice President for Medical Affairs, Sharon Hrynkow, PhD. “We are excited to launch our first clinical sites in the US in the near term, with confidence that the European sites and other global sites will follow in short order.”

Niemann-Pick Disease Type C is a rare genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to a defect in the NPC1 protein which is responsible for cholesterol processing in the cell. NPC causes symptoms in the brain, liver, spleen, lung and other organs and often leads to premature death. There are no approved drug therapies for NPC in the United States and only one approved therapy in Europe.

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com

Safe Harbor Statement:

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.



Contacts
Investor/Media Contact:
Jeffrey L. Tate, Ph.D. COO
Cyclo Therapeutics, Inc.
jeff@cyclodex.com
+1 (386) 418-8060

Thank you so much!!! I was waiting a long time for this day hahaha. I definitely think its still going down too. I will be keeping an eye on it still but wont ever buy back at .19 cents hahaha GLTY

Good for you! I dont see anything bullish about the Form 4 and their last Q was pretty dismal. Notwishstanding this days pop (and perhaps another pop or two) I still think the overall trend is DOWN.

Finally out of this stock woohoo thank you baby J!

Really hoping we can get back to 19 cents so I can get out lol

You've been laffing your losing azz off from around buck...only down around 90%

LMAO!

bump

bump

It looks like it bounced off the .12s pretty well. It is trending upward again, maybe another bounce coming in the next few days? We will see, still have all my shares...

Looks like .11 cents is the next target down.

Lol yep not going as planned, hopefully we have some more volume days ahead of us. I might be here for a while...

Longs now praying they're not stuck in Hotel California...

volume died here, but that 100k bid at .17 gives me hope for next week. Let's get some news!

Light trading day, would be nice to be able to break resistance at .20 but would it be correct to say that this is trading in a channel between .17 and .20? What are the chances of breaking out of that?

3rd day even bigger volume, getting exciting fast!

yup, 2nd day of big volume means something is going on behind the scenes, yesterday was not a fakeout.

Jesus, over 1M volume by noon, something's brewing

@SukhshantiOm, I agree with you, we might see .25 today, would be nice if it would close above .22, yesterday’s high was .225. Let’s see at the end of day if I was right.

bought a bunch of this today, volume before price. Something is definitely in the works here.

we'll see. This is one of the most manipulated stocks on the OTC I've ever been in.

I was in it from the late 90's to 2014 (and a little beyond). currently, I only have a small position.
__________

I originally bot this stock when the OS was under 2 million shares
I was buying this stock when it was trading under 2 cents.

@Lazarus, and the conversation on this board has started up again. I’m looking for a run up into mid .30’s like in December and last May, especially if it’s given some breathing room.